Respiratory syncytial virus (RSV) has eluded active vaccination efforts for more than five
decades and continues to cause substantial morbidity and mortality in infants, the …

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease
in young children and a substantial contributor to respiratory tract disease throughout life …

The invaluable health, economic and social impacts of vaccination are hard to exaggerate.
The ability to stabilize vaccines is urgently required for their equitable distribution without the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its …

Respiratory syncytial virus (RSV) is a human respiratory pathogen which remains a leading
viral cause of hospitalizations and mortality among infants in their first year of life. Here, we …

Soluble HIV-1 envelope glycoprotein (Env) immunogens are a prime constituent of
candidate vaccines designed to induce broadly neutralizing antibodies. Several lines of …

Respiratory syncytial virus (RSV) is a major healthcare concern, especially for immune-
compromised individuals and infants below 5 years of age. Worldwide, it is known to be …

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract
infections in the elderly and in children, associated with pediatric hospitalizations. Recently …

Using computer algorithms and commercial DNA synthesis, one or more ORFs of a
microbial pathogen such as a virus can be recoded and deoptimized by several strategies …

Respiratory syncytial virus (RSV) can cause severe respiratory disease in humans,
particularly in infants and the elderly. However, attempts to develop a safe and effective …